Osaka, Japan and Utrecht, the Netherlands

May 4th, 2020

In a world with COVID-19 travel restrictions, MILabs has remotely completed the installation of a new E-Class VECTor6 system at the Osaka University of Pharmaceutical Sciences, Osaka, Japan. With the help of a local technician, this top-of-the-line multimodality PET/SPECT/CT system was put into operation by remote control from MILabs’ support facility in the Netherlands.

Osaka installations

According to Prof. Takashi Temma, Ph.D., Director of the Department of Biofunctional Analysis: “We are impressed by the robust design and remote support capabilities of this complex multimodal PET-SPECT-CT system. Besides delivering excellent imaging performance for each modality, the system also has the unique ability to run two assays labeled with different PET isotopes or PET/SPECT isotopes concurrently, in the same animal. Since we develop new diagnostic probes for biofunctional analysis, this MILabs system gives us the power advantage of within-subjects designs, resulting in more reliable results and the use of fewer disease models.”

Prof. Frederik Beekman, Ph.D., CEO/CSO comments: “We are excited that despite travel bans, we could get Prof. Temma’s system up and running for his routine use through remote control from our offices. The unique concurrent imaging capabilities of this multimodal system enables in a single imaging session to deliver more statistically reliable results than any other multimodal in-vivo imaging setup.”

About Osaka University of Pharmaceutical Sciences
The Osaka University of Pharmaceutical Sciences is dedicated to education and research in pharmaceutical sciences. Among its research objectives are the development of diagnostic and therapeutic methods using animal disease model by employing molecular imaging for early functional diagnosis, and evaluation of therapeutic effects on cancers. More specifically, the Biofunctional Analysis laboratory is focused on the design and development of radiolabeled probes for PET and SPECT imaging.

About MILabs B.V.

This fast-growing Dutch company has a history of providing a continuum of innovations to expand the applications preclinical molecular imaging. With its latest adaptive platform, MILabs has succeeded at commercializing a scalable imaging platform, able to accommodate PET, SPECT, Optical and CT imaging either as stand-alone or fully integrated modalities on a single integrated system. For the commercialization of this preclinical imaging platform, MILabs was awarded the Commercial Innovation of the Year 2018 at the World Molecular Imaging Congress. For more information, visit:  www.milabs.com or contact MILabs at [email protected]

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →

MILabs remotely installs from the Netherlands new E-Class PET/SPECT/CT at Osaka University of Pharmaceutical Sciences

Osaka, Japan and Utrecht, the Netherlands May 4th, 2020 In a world with COVID-19 travel …

Read More →

University of Torino (UNITO) acquires an advanced MILabs molecular imaging system

The University of Torino (UNITO) acquires advanced MILabs molecular imaging system for the design of …

Read More →

Truman VA acquires VECTor preclinical imaging system featuring exclusive multimodal synergy capabilities.

Columbia, Missouri, USA and Utrecht, the Netherlands April 9th, 2020 Harry S. Truman Memorial Veterans’ …

Read More →

Cyprus-based EPOS-Iasis acquires MILabs innovative Optical/CT system

Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals …

Read More →

MILabs enhances micro-CT for Coronavirus (COVID-19) research.

March 19, 2020 – Utrecht, the Netherlands Based on recent scientific research, diagnostic X-ray CT …

Read More →

The Julius Wolf Institute at the Charité installs mission-critical MILabs microCT for in-vivo studies of musculoskeletal regeneration

25 February 2020 – Berlin-Germany and Utrecht, Netherlands, The Julius Wolff Institute for Biomechanics and …

Read More →

MILabs realizes a breakthrough in preclinical oncology imaging by eliminating the positron range effect of 89Zr-immunoPET

February 15, 2020 – Utrecht, the Netherlands Researchers at MILabs B.V. have succeeded at imaging …

Read More →
Scroll to Top